Pediatric Pneumococcal Serotypes in 4 European Countries
Germaine Hanquet
1 , Esther Kissling, Asuncion Fenoll, Robert C. George, Agnes Lepoutre, Tinne Lernout, David Tarragó, Emmanuelle Varon, and Jan Verhaegen
Author affiliations: Author affiliations: Scientific Institute of Public Health, Brussels, Belgium (G. Hanquet, E. Kissling, T. Lernout); Belgian Knowledge Centre, Brussels (G. Hanquet); Instituto de Salud Carlos III, Madrid, Spain (A. Fenoll, D. Tarragó,); Health Protection Agency, London, UK (R. George); Institut de Veille Sanitaire, Saint Maurice, France (A. Lepoutre); Hôpital Européen G. Pompidou, Paris, France (E. Varon); Katholieke Universiteit Leuven Pneumococcus Reference Laboratory, Leuven, Belgium (J. Verhaegen)
Main Article
Figure 5
Figure 5. Incidence of invasive pneumococcal disease in children caused by serotype 19A for children <5 years of age (black lines) and 5–14 years of age (red lines), in A) Spain, B) Belgium, C) England and Wales, and D) France, 1996–2006. Estimated vaccine coverage is the annual number of PCV7 schedules per 100 children <2 years of age, assuming an average of 3 doses administered to each child. Vaccine coverage is not visible for England and Wales because it remains <1%.
Main Article
Page created: August 28, 2011
Page updated: August 28, 2011
Page reviewed: August 28, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.